Home > Search Results: Kim, D.W.
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
UAB Digital Repository of Documents 2 records found  Search took 0.01 seconds. 
1.
15 p, 598.6 KB Five Year Survival Update From KEYNOTE-010 : Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC / Herbst, Roy S (Section of Medical Oncology. Yale Comprehensive Cancer Center. Yale University School of Medicine) ; Garon, E.B. (David Geffen School of Medicine. University of California Los Angeles) ; Kim, D.W. (Seoul National University Hospital. Seoul National University College of Medicine) ; Cho, B.C. (Yonsei Cancer Center. Yonsei University College of Medicine) ; Gervais, R. (Centre François Baclesse (Caen, França)) ; Perez-Gracia, J.L. (Clínica Universidad de Navarra) ; Han, J.Y. (Center for Lung Cancer. National Cancer Center) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Forster, M.D. (UCL Cancer Institute/University College London Hospitals) ; Monnet, Isabelle (Centre Hospitalier Intercommunal de Créteil) ; Novello, Silvia (Department of Oncology. University of Turin. Azienda Ospedaliero Universitaria San Luigi) ; Gubens, M.A. (University of California. San Francisco) ; Boyer, M. (Chris O'Brien Lifehouse) ; Su, W.C. (National Cheng Kung University Hospital) ; Samkari, A. (Merck & Co.. Inc.) ; Jensen, E.H. (Merck & Co.. Inc.) ; Kobie, J. (Merck & Co.. Inc.) ; Piperdi, B. (Merck & Co.. Inc.) ; Baas, Pieter (The Netherlands Cancer Institute (Amsterdam, Països Baixos))
Introduction: In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in patients with previously treated, advanced NSCLC with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥50% and ≥1%. [...]
2021 - 10.1016/j.jtho.2021.05.001
Journal of Thoracic Oncology, Vol. 16 Núm. 10 (october 2021) , p. 1718-1732  
Detailed record - Creative Commons
2.
10 p, 290.8 KB Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer / Peters, S. (Lausanne University Hospital) ; Camidge, David Ross (University of Colorado) ; Shaw, A. T. (Massachusetts General Hospital (Boston)) ; Gadgeel, S. (University of Michigan) ; Ahn, Jin Seop (Samsung Medical Center. Sungkyunkwan University School of Medicine) ; Kim, Dong-Wan (Seoul National University Hospital) ; Ou, S. H. I. (School of Medicine) ; Pérol, M. (Department of Medical Oncology. Léon Bérard Cancer Center) ; Dziadziuszko, R. (Department of Oncology and Radiotherapy. Medical University of Gdansk) ; Rosell, R. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Zeaiter, A. (F. Hoffmann-La Roche) ; Mitry, E. (F. Hoffmann-La Roche) ; Golding, S. (F. Hoffmann-La Roche) ; Balas, B. (F. Hoffmann-La Roche) ; Noe, J. (F. Hoffmann-La Roche) ; Morcos, P. N. (Roche Innovation Center) ; Mok, T. (State Key Laboratory of South China. Chinese University of Hong Kong)
BACKGROUND: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). [...]
2017 - 10.1056/NEJMoa1704795
The New England journal of medicine, Vol. 377 Núm. 9 (31 2017) , p. 829-838  
Detailed record -

See also: similar author names
5 Kim, D.
16 Kim, D. H.
2 Kim, D. J.
1 Kim, D.B.
4 Kim, D.H.
1 Kim, D.K.
1 Kim, D.Y.
1 Kim, Dae-Jung
1 Kim, Daeyeon
4 Kim, Daniel
1 Kim, Dennis
1 Kim, Do Hyung
4 Kim, Do-Heyoung
1 Kim, Dong Ki
1 Kim, Dong-Hwan
1 Kim, Dong-Wan
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with